Hierarchical Microcarriers Loaded with Peptide Dendrimer-Grafted Methotrexate for Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is one of the leading causes of disability due to the autoimmune destruction of synovial joints. Great efforts have been put into developing multifunctional drug delivery systems for delaying the progression of RA. Herein, a novel locally injectable, hierarchically structured delivery system with a hyaluronic acid (HA) microparticle and an MTX-conjugated nanoparticle for promoted RA treatment is proposed. In this system, MTX is chemically grafted onto a peptide dendrimer-based nanoparticle (G-MTX). These nanoparticles are encapsulated inside HA microparticles (H-G-MTX) using microfluidics to realize the system. The G-MTX can be released from the degradable HA microparticles in the acidic environment of inflamed RA joints. As the G-MTX shows an enhanced intracellular delivery of the conjugated MTX, the H-G-MTX can reverse the dominant macrophage phenotype from M1 to M2. Through a collagen-induced arthritis (CIA) rat model, the great therapeutic outcomes of this hierarchically structured delivery system are demonstrated, including inflammation reduction, cartilage protection, and bone mineral density promotion. These results indicate that the proposed hierarchical delivery system has potential clinical value in the treatment of RA and other diseases. A novel locally injectable, hierarchically structured delivery system with hyaluronic acid particles and a methotrexate conjugated nanoparticle which enables precise accumulation, responsive release, and amplifies efficacy of methotrexate and target therapy in rheumatoid arthritis (RA) joints is studied. The system-alleviated bone destruction and cartilage damage and these results indicate the potential of this system for RA treatment.image (c) 2023 WILEY-VCH GmbH